Objective: Metastases of the adrenal gland are a frequent ®nding in patients with malignant tumors like bronchogenic carcinoma or breast cancer. Only limited and con¯icting data on adrenocortical function in these patients are available. Design: Cross-sectional study. Methods: We investigated the impact of adrenal macrometastases on adrenocortical function in a series of 28 tumor patients using the ACTH 1±24 stimulation test and dexamethasone suppression test. Seven normal controls (Con), eleven patients without adrenal metastases (No Met), eight patients with unilateral (Uni Met) and nine patients with bilateral adrenal metastases (Bil Met) were investigated. Results: The prevalence of adrenal insuf®ciency was low in our study population, with only two of nine patients with bilateral metastases having subclinical adrenocortical insuf®ciency. In the remaining patients with uni-or bilateral metastases, baseline and stimulated cortisol concentrations were higher than in controls and cancer patients without metastases (baseline cortisol (in nmol/l): Con: 307633.2 vs Uni Met: 440 6 53.5, and Bil Met: 637.6 6 92.1, P 0.04 by ANOVA; cortisol 60 min after ACTH 1±24 : Con: 794.6 6 41.2 vs Uni Met: 990.8 6 92.9, and Bil Met: 1151.4 6 155.5, P 0.03 by ANOVA). Simultaneously, baseline and stimulated serum aldosterone concentrations were signi®-cantly blunted in the tumor groups. Conclusions: Adrenal insuf®ciency is infrequent and develops only in patients with bilateral metastases. However, the majority of patients have activation of the hypothalamic±pituitary±adrenal axis despite adrenal metastases with strongly elevated cortisol concentrations.
Introduction
Metastases of the adrenal gland are a frequent ®nding in patients with advanced solid tumors (1±4). In autopsy series, the prevalence of adrenal metastases was 36± 44% in bronchiogenic carcinoma (4, 5) , 20±58% in breast cancer (2, 4, 5) , 50±60% in malignant melanoma (4, 6) , 11±21% in gastric cancer (2, 4, 7) and 4.8±14% in colorectal cancer (4, 8) . In most of these patients, the metastases remained clinically silent and did not require speci®c therapy.
Adrenocortical insuf®ciency is a rare but potentially lethal disease. Autoimmune adrenalitis is the most frequent cause accounting for 70% of the cases, followed by adrenal tuberculosis (15%) (9, 10) . Also, adrenal macrometastases are a well-recognized but infrequent cause of adrenal insuf®ciency (11±16), and were already reported in the original publication of Addison (17) . In two larger series, Cedemark & Sjoberg (18) and Redman et al. (19) reported diverging results concerning the prevalence of adrenocortical insuf®ciency in patients with adrenal metastases. Both studies reported limited hormonal data and were hampered by the lack of an appropriate control group. This is especially necessary since cancer patients may have an activated hypothalamic±pituitary±adrenal axis, due to increased physiological stress (20) and interactions between the tumor, the immune and the endocrine system (21) . In this study, we evaluated the adrenocortical responsiveness to exogenous adrenocorticotropin (ACTH) in a series of seven normal controls, eleven patients without adrenal metastases, eight patients with unilateral and nine patients with bilateral macrometastases. Our data showed that adrenal insuf®ciency is only found in patients with large (> 4 cm) bilateral adrenal metastases.
In addition, we have demonstrated that cancer patients generally show activation of the hypothalamic±pituitary axis which is more pronounced in the advanced stage.
Patients and methods

Patients
Seven normal controls, eleven tumor patients without adrenal metastases (45.5% with other distant metastases), eight tumor patients with unilateral adrenal metastases (62.5% with other distant metastases) and nine tumor patients with bilateral metastases (77.7% with other distant metastases) were studied in a prospective fashion (for clinical data see Table 1 ). The 17 patients with uni-or bilateral metastases were recruited from a total of 34 patients with this condition treated at our institution during a 2-year period. The remaining 17 patients were excluded for the reasons listed below. Exclusion criteria were: disorders of the hypothalamic±pituitary±adrenal axis, glucocorticoid therapy, renal insuf®ciency (creatinine >2.0 mg/dl), liver insuf®ciency, or sepsis/infection. Also, patients with ectopic ACTH syndrome were excluded. All patients and control subjects gave their written informed consent. The study protocol was approved by the ethical committee of the University Hospital of Wu È rzburg.
The patients were carefully evaluated for signs and symptoms of adrenal insuf®ciency. All patients underwent routine computed tomography of the abdomen with administration of oral and i.v. contrast material as part of the staging procedures. Adrenal metastases were diagnosed if a signi®cant adrenal mass was present (>1 cm), which showed at least two of the following criteria: irregular boundaries, irregular contrast enhancement, increase in size during follow-up or regression after systemic chemotherapy (22, 23) .
ACTH 1±24 stimulation test
At 0900 h all subjects underwent an ACTH stimulation test using 250 mg ACTH 1±24 (Synacthen; Ciba-Geigy, Wehr am Rhein, Germany). An indwelling canula was inserted in an antecubital vein at À60 min, and the subjects were seated in an upright position throughout the test. At À30 and 0 min, blood was drawn for baseline determination of plasma ACTH, plasma renin activity, serum cortisol and serum aldosterone. After bolus injection of ACTH 1±24 , blood was drawn at 30, 60 and 90 min for determination of serum cortisol and aldosterone.
Diagnostic criteria for adrenal insuf®ciency
Overt adrenal insuf®ciency was de®ned by standard criteria as a serum cortisol response to stimulation with ACTH 1±24 below 560 nmol/l (<20 mg/dl) (9, 10). Subclinical adrenal insuf®ciency was de®ned as an elevated ACTH:cortisol (pmol/l:nmol/l) ratio >0.028 (24) and a missing response to stimulation with ACTH 1±24 (increase below 90 nmol/l (<3 mg/dl)), but normal baseline or maximum stimulated cortisol concentrations above 560 nmol/l.
Dexamethasone suppression test
In a subgroup of six normal subjects and twelve patients, suppressibility of plasma ACTH and serum cortisol by dexamethasone was determined. The remaining sixteen patients could not be studied for the following reasons: initiation of chemotherapy, withdrawn consent, and deterioration of clinical status. The subjects received 3 mg dexamethasone orally at 2300 h, and plasma ACTH and serum cortisol levels were determined at 0800 h the following morning. The dose of 3 mg instead of 2 mg was used to reduce the number of false positive test results which may be seen in cancer in-patient cohorts. The 3 mg dexamethasone suppression test has been evaluated in our institution previously (25) .
Assays
All hormones were determined with commercially available assays. Plasma ACTH was measured by an immunoluminometric assay (LUMItest; Brahms Diagnostica, Berlin, Germany), the plasma renin activity by RIA (Sorin), serum cortisol and serum aldosterone by RIA (DPC; Biermann GmbH, Bad Nauheim, Germany). The intra-and interassay variability was below 10% for all assays.
Statistics
After exclusion of patients with adrenal insuf®ciency (n 2) the values of each patient group are expressed as means 6 S.E.M. Signi®cance of differences between groups were determined by ANOVA with correction for multiple comparisons using a PowerMacintosh computer and the StatView 4.5 program. P < 0.05 was considered statistically signi®cant.
Results
Prevalence of adrenocortical insuf®ciency in patients with adrenal metastases
Symptoms suggestive of adrenocortical insuf®ciency were present in a substantial percentage of patients with and without adrenal metastases (Table 2 ). In contrast, the prevalence of adrenal insuf®ciency using biochemical criteria in these patients was low. None of the patients had evidence of overt adrenocortical insuf®-ciency. However, two of nine patients with large bilateral metastases had elevated ACTH:cortisol ratios and did not respond to stimulation with ACTH 1±24 (Fig.  1 and Table 3 ), suggesting mild impairment of adrencortical function (subclinical adrenal insuf®-ciency). Both patients received glucocorticoid replacement therapy, without clinical improvement. They were excluded from further analyses.
Cortisol and aldosterone response to ACTH 1±24
Compared with normal control subjects, tumor patients, especially with metastases, had higher baseline and stimulated cortisol concentrations (Fig. 2a) . Simultaneously, serum aldosterone concentrations were lower in tumor patients compared with controls ( Fig. 2b) . Plasma renin activity (ng/ml per h) was higher in tumor patients, but the difference did not reach statistical signi®cance (controls: 0.8 6 1.4; patients without metastases: 1.6 6 0.7; patients with unilateral metastases: 1.1 6 0.4; patients with bilateral metastases: 1.1 6 0.4; P not signi®cant).
Dexamethasone suppression test
Six tumor patients without metastases, three patients with unilateral metastases and three patients with bilateral metastases underwent dexamethasone suppression testing with 3 mg dexamethasone. Dexamethasone suppressed plasma ACTH concentrations both in controls and tumor patients. In contrast, serum cortisol concentrations (nmol/l) were incompletely suppressed in ten of twelve patients (controls: 30 6 5, normal range <55 nmol/l; patients without metastases: 110 6 30; patients with unilateral metastases: 100 6 40; patients with bilateral metastases: 470 6 115).
Discussion
Adrenal metastases are a very frequent ®nding in patients with bronchogenic carcinoma. In a retrospective study, Silvestri et al. (26) found adrenal metastases in 26 of 173 patients (15%) using computed tomography, with a positive correlation between tumor stage and the prevalence of adrenal metastases. Salvatierra et al. (27) reported a prevalence of 7.5% in 146 patients with potentially resectable non-small cell carcinomas. However, studies using computed tomography may substantially underestimate the frequency of adrenal metastases. For example, Pagani (28) reported on 32 patients with normal adrenal morphology on computed tomography who underwent a ®ne-needle biopsy of the adrenal. Of these, four patients (12%) were found to have micrometastases of the adrenal gland.
Compared with the prevalence of adrenal metastases, adrenocortical insuf®ciency in these patients seems to 
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bilat. the diagnosis of adrenal insuf®ciency seems to be questionable, because baseline cortisol concentrations were already high, exceeding 25 mg/dl (700 nmol/l) which suggests near-maximal endogenous stimulation of the adrenal cortex. Neither in this nor in the other articles mentioned above were plasma ACTH concentrations given although plasma ACTH is an important parameter if primary adrenal insuf®ciency is suspected (24) . In summary, the prevalence of adrenal insuf®ciency in patients with adrenal metastases reported in the literature ranges from 0 to 80%. These differences seem to be mainly due to the preselection of patients and variable criteria for the diagnosis of adrenal insuf®ciency.
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We studied nine patients with bilateral adrenal metastases and compared the results with that of eleven tumor patients without metastases and eight tumor patients with unilateral metastases. These patients comprised all eligible patients with adrenal metastases during a 2-year period at our institution. In addition, we studied seven normal control subjects. Clinically, tumor patients frequently had signs and symptoms suggestive of adrenal insuf®ciency. Since no clear correlation between the clinical data and adrenocortical function testing was found, these symptoms are more likely due to the underlying malignancy than caused by a relative glucocorticoid de®cit. Clinical assessment of adrenal insuf®ciency, therefore, is of little value in these patients, and the prevalence of adrenal impairment will be overestimated if the diagnosis of adrenal insuf®ciency is based on features like weakness, fatigue, anorexia, weight loss, and vomiting only.
Using standard criteria (serum cortisol <560 nmol/l after ACTH 1±24 stimulation (9, 10)), none of our patients with adrenal metastases had overt adrenal insuf®ciency. Instead, patients with adrenal metastases had increased glucocorticoid concentrations as may be seen in patients with chronic stress. The cortisol excess was more pronounced in patients with bilateral than in patients with unilateral adrenal metastases. Stimulation of adrenocortical function in tumor patients may result from increased in¯ammatory cytokine secretion of immunocompetent cells in response to the tumor (32, 33) or by the tumor itself (34), such as tumor necrosis factor-a (35), interleukin-1 (36) and interleukin-6 (37) or by the increased physical and mental stress of tumor patients (20, 21, 38) . These data suggest that plasma ACTH and cortisol concentrations within the lower normal range of healthy subjects may not be suf®cient in re¯ecting`eucortisolism' in patients with advanced tumor stages. In these subjects, higher cortisol concentrations are required to maintain homeostasis. Therefore, diagnostic evaluation of patients with bilateral metastases and therapeutic recommendations for suspected adrenal insuf®ciency have to take into account the fact that the hypothalamic±pituitary± adrenal axis is activated in tumor patients. Elevated plasma ACTH concentrations or an elevated ACTH:cortisol ratio are sensitive indicators of adrenal insuf®ciency (10, 24) . Elevation of plasma ACTH characteristically precedes the onset of overt adrenal insuf®ciency (39) . Using the ACTH:cortisol ratio, two of nine patients with bilateral adrenal metastases had mild impairment of adrenocortical function. We de®ned this type of dysfunction as subclinical adrenal insuf®ciency. Baseline cortisol concentrations were in the upper normal range in both patients, but the response to stimulation with ACTH was missing. Both patients had large metastases exceeding 4 cm on both sides. Glucocorticoid and mineralocorticoid treatment was started, but clinical improvement was missing, and both patients died within 2 months due to progressive disease. Our ®ndings and data from the literature suggest that patients with bilateral adrenal metastases should be evaluated for the presence of adrenal insuf®ciency. Patients with large metastases are especially at risk for adrenal insuf®ciency and should receive careful follow-up even if baseline testing is normal. In our opinion, the ACTH:cortisol ratio may be superior to ACTH 1±24 testing since interpretation of the results of the ACTH stimulation test is dif®cult due to the various degrees of stress to which tumor patients are exposed.
We found an increased cortisol response to ACTH stimulation concomitantly with a decreased aldosterone response. These data favor a shift in adrenal steroidogenesis from mineralocorticoid secretion towards glucocorticoid secretion, a characteristic feature found in patients with critical illness (40±42). These data have led to the conclusion that the function of the zona glomerulosa and reticularis is impaired in critical illness. We found similar changes in steroid hormone pro®les in this study suggesting impairment of zona glomerulosa function in tumor patients. The degree of dysfunction was more severe in patients with adrenal metastases than in patients without adrenal metastases. This may be explained by the advanced tumor stages of the former patients associated with increased physical stress. However, a stimulatory paracrine effect of adrenal metastases on glucocorticoid secretion in these patients cannot be excluded. Whether this is mediated at the level of the hypothalamic pituitary unit by increased ACTH release, by direct stimulation of the adrenal cortex via in¯ammatory cytokines (37) or by humoral factors produced by the adrenal metastases (e.g. pro-opiomelanocortin peptides, cytokines, other neuroendocrine peptides) has to be determined. The results of the dexamethasone suppression test are in favor of the latter possibility. Plasma ACTH concentrations were readily suppressible in these patients in response to dexamethasone, whereas cortisol secretion was partially resistant. The discrepancy between plasma ACTH and cortisol response to dexamethasone was especially evident in patients with bilateral adrenal metastases, supporting the concept that glucocorticoid secretion may be in¯uenced by locally produced factors in adrenal metastases which may act as paracrine (and partially ACTH-independent) stimuli for cortisol synthesis. Whether this hypothesis turns out to be true has to be proven in a larger cohort of patients with adrenal metastases.
